130403-91-7

Usage

Uses

(S)-3-((tert-Butyldimethylsilyl)oxy)pyrrolidin-2-one can be used as Nrf2 activators.

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 34368-52-0 (S)-3-hydroxypyrrolidin-2-one 

Downstream Products

• 182197-78-0 (S)-1-benzyloxycarbonyl-3-(tert-butyldimethylsilyloxy)-2-pyrrolidinone 
• 1338327-08-4 (S)-1-(4-bromo-3-chlorobenzyl)-3-(tert-butyldimethylsilyloxy)pyrrolidin-2-one 
• 1338327-06-2 (S)-4-amino-6-(4'-((3-(tert-butyldimethylsilyloxy)-2-oxopyrrolidin-1-yl)methyl)-2'-chlorobiphenyl-4-yl)-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one 
• 1338327-07-3 (S)-3-(tert-butyldimethylsilyloxy)-1-(3-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)pyrrolidin-2-one 
• 1257424-03-5 C₁₈H₂₉NO₄Si 
• 1257423-98-5 (2R,3S)-1-benzyloxycarbonyl-3-(tert-butyldimethylsilyloxy)-2-(pyridin-2-ylthio)-1-pyrrolidine 
• 1257423-95-2 (1S,8R,8aR)-8-benzyloxy-1-(tert-butyldimethylsilyloxy)-2,3,8,8a-tetrahydroindolizin-5(1H)-one 
• 182058-02-2 (S)-1-(2-Azido-benzoyl)-3-(tert-butyl-dimethyl-silanyloxy)-pyrrolidin-2-one 

Relevant academic research and scientific papers

Synthesis of the chiral intermediate of batzelladines A and B

The title compound (S, Z)-methyl 2-[3-(tert-butyldimethylsilyloxy)pyrrolidin-2-ylidene]acetate(6) has been stereoselectively synthesized by the Reformatsky coupling reaction, and the absolute configuration of 6 was determined by1H NMRand single-crystal X-ray diffraction.

Evolution of a Scale-Up Synthesis to a Potent GluN2B Inhibitor and Its Prodrug

This paper describes the efficient scale-up synthesis of the potent negative allosteric glutamate N2B (GluN2B) inhibitor 1 (BMS-986169), which relies upon a stereospecific SN2 alkylation strategy and a robust process for the preparation of its

ARYLOXYACETYLINDOLES AND ANALOGS AS ANTIBIOTIC TOLERANCE INHIBITORS

The disclosure provides compounds and pharmaceutical compositions of aryloxyacetylindoles compounds and analogs useful for treating chronic and acute bacterial infections. Certain of the compounds are compounds of general Formula (I) (I) or a pharmaceutically acceptable salt or prodrug thereof. Certain compounds of this disclosure are MvfR inhibitors. MvfR inhibitors reduce the formation of antibiotic tolerant bacterial strains and are useful for treating Gram-negative bacterial infections and reducing the virulence of Pseudomonas aeruginosa. Methods of treating bacterial infections in a subject, including Pseudomonas aeruginosa infections, are also provided by the disclosure.

(R)-3-((3S,4S)-3-FLUORO-4-(4-HYDROXYPHENYL)PIPERIDIN-1-YL)-1-(4-METHYLBENZYL)PYRROLIDIN-2-ONE AND ITS PRODRUGS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the NR2B NMDA receptor and may be useful for the treatment of various disorders of

Selective NR2B Antagonists

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the c

4 -AMINO -7,8- DIHYDROPYRIMIDO [5, 4 - F] [1, 4] OXAZEPIN- 5 ( 6H) - ONE BASED DGAT1 INHIBITORS

DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro- drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, diabetes and obesity wherein, R1, R2, R3, R4, X2, q, Y1, Y2, n, Q and Z are as defined in the description.

A concise diastereoselective approach to the left-hand side of batzelladine A

A highly diastereoselective three-component coupling reaction has been used in a concise approach to the left-hand side of batzelladine A. The stereoselectivity of this reaction, along with related observations described herein, provides insight into the mechanism of this reaction.

Samarium diiodide promoted generation and asymmetric hydroxyalkylation of N,O-diprotected (3S)-3-pyrrolidinol 2-carbanions

(Chemical Equation Presented) The N,O-diprotected chiral nonracemic 2-pyridyl 3-pyrrolidinol-2-yl sulfide 5a undergoes efficient SmI2 mediated reduction to give the N,O-diprotected 3-pyrrolidinol 2-carbanion intermediate D, which reacted under

Synthesis of optically active vasicinone based on intramolecular aza-Wittig reaction and asymmetric oxidation

Both optical isomers of a quinazoline alkaloid, vasicinone, were synthesized by two different methods. The first method used (3S)-3-hydroxy-γ-lactam as a chiral synthon, which was, after O-TBDMS protection, o-azidobenzoylated followed by treatment with tri-n-butylphosphine to afford (S)-(-)-vasicinone via the tandem Staudinger/intramolecular aza-Wittig reaction. The second method utilized asymmetric oxygenation of deoxyvasicinone with (1S)-(+)- or (1R)-(-)-(10-camphorsulfonyl)oxaziridine (the Davis reagent), respectively. The aza-enolate anion of deoxyvasicinone was treated with (S)-(+)-reagent to afford (R)-(+)-vasicinone in 71% ee, while the reaction with (R)-(-)-reagent gave (S)-(-)-vasicinone in 62% ee. The optical purity was analyzed by HPLC on specially modified cellulose as a stationary phase. These results provided a facile method to prepare both optical isomers of vasicinone and confirmed the recently reversed stereochemistry of natural (-)-vasicinone.

3- or 4-substituted oxotremorine derivatives

This disclosure describes novel 3 or 4 substituted oxotremorine derivatives having polar substituted oxygen or sulfur groups. The compounds have cholinergic activity. Also disclosed are methods for treating diseases of the central nervous system in mammals employing the compounds, pharmaceutical preparations containing the compounds and processes for the production of the compounds.